Comparison of total oxidative state, total antioxidative state, serum paraoxonase activity, and thiol levels before and after 6 months of treatment in patients with multiple sclerosis who have been recently started on new therapy agents

TL;DR

This study examines how oxidative stress and antioxidant levels change in multiple sclerosis patients after six months of immunomodulator therapy.

Contribution

The study identifies specific oxidative stress and antioxidant markers that respond to immunomodulator therapy in multiple sclerosis.

Findings

After six months of treatment, patients showed significant increases in native thiol, PON, and TAS levels.

Oxidative stress indicators like TOS and OSI decreased, suggesting a protective effect of immunomodulator therapy.

No significant correlation was found between disease duration, sex, or therapy agents and oxidative stress parameters.

Abstract

The objective of this study was to establish the oxidative stress determiners as a total oxidative state (TOS), total antioxidative state (TAS), paraoxonase (PON) activity, oxidative stress index (OSI), and thiol/disulfide levels before and after 6 months of immunomodulator therapy in patients who were diagnosed according to the revised McDonald Criteria.

Thirty-nine patients were included in our study who were diagnosed according to the revised McDonald Criteria, approved to participate in the study, and had been treated in the neurology inpatient clinic or presented in the neurology outpatient clinic of Ankara Yıldırım Beyazıt University Atatürk Training and Research Hospital. Blood samples were collected from patients before treatment and six months after treatment. The venous blood samples of the patients were evaluated for routine biochemical tests, TOS, TAS, PON activity, OSI, and thiol/disulfide levels.

The oxidative stress parameter levels of blood samples obtained before and after 6 months of the treatment were compared. The blood samples obtained after 6 months of therapy exhibited statistically significant results, including elevated levels of native thiol/total thiol (SH/SH+SS), PON, and TAS (p = 0.001). No significant relation was observed between the duration of disease, sex, used therapy agents, and oxidative stress parameters.

In this study, we determined that TOS and OSI, which are indicators of oxidative stress, and TAS and PON, which exhibit antioxidative activity, can be employed to evaluate the therapy response. Additionally, we found that immunomodulator therapies can exhibit a protective effect, as evidenced by a reduction in oxidative stress indicators.